Search

Your search keyword '"Vivas, C. Santos"' showing total 17 results
Start Over Author "Vivas, C. Santos"
17 results on '"Vivas, C. Santos"'

2. 588P Genomic landscape of acquired resistance to first-line (1L) anti-EGFR treatment in metastatic colorectal cancer (mCRC) beyond the classical EGFR pathway: Findings from the PLATFORM-B study

Author

Martelli, V., Barrull, J. Vidal, Rodriguez, C. Fernandez, Toledo, R.D.A., Gibert, J., Alfonso, P. García, Paez, D., Alonso-Orduna, V., Gomez España, M.A., Vivas, C. Santos, Ogaya, G. Duran, Fernandez, M.E. Elez, Garcia-Carbonero, R., Monteagudo, R. Ferreiro, Mozo, J.L. Manzano, Paricio, B. Bellosillo, Tabernero, J., Soler, R. Salazar, Aguilar, E. Aranda, and Viladot, C. Montagut

Published
2024
Full Text
View/download PDF

3. 511MO Third line rechallenge with cetuximab (Cet) and irinotecan in circulating tumor DNA (ctDNA) selected metastatic colorectal cancer (mCRC) patients: The randomized phase II CITRIC trial

Author

Vivas, C. Santos, Barrull, J. Vidal, Rodriguez, C. Fernandez, Ballabrera, F. Salvà, Alonso-Orduna, V., Garcia-Carbonero, R., Losa, F., Llavero, N. Tarazona, Aguileria, M.J. Safont, Herrero, F. Rivera, Romero, L. Layos, Morales, M.J. Ortiz, Salud, A., Alcaide-Garcia, J., Paez, D., Hernandez-Yagüe, X., Gallego, R. Alvarez, Vera, R., Paricio, B. Bellosillo, and Viladot, C. Montagut

Published
2024
Full Text
View/download PDF

4. RAS mutant allele fraction in plasma predicts benefit to anti-angiogenic based first-line treatment in metastatic colorectal cancer

Author

Martini, G., primary, Elez, E., additional, Mancuso, F.M., additional, España, M A Gomez, additional, Caratù, G., additional, Matito, J., additional, Martinez, G Argiles, additional, Margalef, N Mulet, additional, Morales, M J Ortiz, additional, Montana, F J Ros, additional, Garcia, A., additional, Comas, R., additional, Vivas, C Santos, additional, Perez-Lopez, R., additional, Nuciforo, P.G., additional, Casanovas, O., additional, Dienstmann, R., additional, Tabernero, J., additional, Aguilar, E Aranda, additional, and Vivancos, A., additional

Published
2019
Full Text
View/download PDF

5. Clinical relevance of circulating tumour (ct)DNA genotyping for first-line cetuximab-based treatment monitoring in metastatic colorectal cancer (mCRC): A prospective multicentric study

Author

Barrull, J Vidal, primary, Casadevall, D., additional, Fernandez, M.C., additional, Castro-Henriques, M., additional, García-Alfonso, P., additional, Martin-Cullell, B., additional, Alonso-Orduna, V., additional, Alonso, R M Rodríguez, additional, Benavides, M., additional, Vivas, C Santos, additional, Fernández, E Elez, additional, Garcia-Carbonero, R., additional, Ferreiro, R., additional, Manzano, J.L., additional, Losa, F., additional, Salazar, R., additional, Tabernero, J., additional, Aguilar, E Aranda, additional, Bellosillo, B., additional, and Viladot, C Montagut, additional

Published
2019
Full Text
View/download PDF

6. A two arm phase II study of FOLFIRI in combination with standard or escalating dose of cetuximab as first line treatment for metastatic colorectal cancer: Everest 2 final results

Author

UCL - SSS/IREC/MIRO - Pôle d'imagerie moléculaire, radiothérapie et oncologie, UCL - (SLuc) Unité d'oncologie médicale, Chiritescu, G, Dumon, K, Mercadé, T Macarulla, Lang, I, Vivas, C Santos, Papai, Z, Janssens, J, Hendrickx, K, Pracht, M, Van den Eynde, Marc, Taïeb, J, Moons, V, Geboes, K, Van Laethem, J, Greil, R, Cervantes, A, Vergauwe, P, Ferrante, M, Vanderstraeten, E, Fridrik, M, Wöll, E, Limón, M, Rivera, F, Sagaert, X, Tejpar, S, Van Cutsem, E, ESMO 20th World Congress on Gastrointestinal Cancer, UCL - SSS/IREC/MIRO - Pôle d'imagerie moléculaire, radiothérapie et oncologie, UCL - (SLuc) Unité d'oncologie médicale, Chiritescu, G, Dumon, K, Mercadé, T Macarulla, Lang, I, Vivas, C Santos, Papai, Z, Janssens, J, Hendrickx, K, Pracht, M, Van den Eynde, Marc, Taïeb, J, Moons, V, Geboes, K, Van Laethem, J, Greil, R, Cervantes, A, Vergauwe, P, Ferrante, M, Vanderstraeten, E, Fridrik, M, Wöll, E, Limón, M, Rivera, F, Sagaert, X, Tejpar, S, Van Cutsem, E, and ESMO 20th World Congress on Gastrointestinal Cancer

Published
2018

7. A two arm phase II study of FOLFIRI in combination with standard or escalating dose of cetuximab as first line treatment for metastatic colorectal cancer: Everest 2 final results

Author

Chiritescu, G., primary, Dumon, K., additional, Mercadé, T. Macarulla, additional, Lang, I., additional, Vivas, C. Santos, additional, Papai, Z., additional, Janssens, J., additional, Hendrickx, K., additional, Pracht, M., additional, Van den Eynde, M., additional, Taïeb, J., additional, Moons, V., additional, Geboes, K., additional, Van Laethem, J., additional, Greil, R., additional, Cervantes, A., additional, Vergauwe, P., additional, Ferrante, M., additional, Vanderstraeten, E., additional, Fridrik, M., additional, Wöll, E., additional, Limón, M., additional, Rivera, F., additional, Sagaert, X., additional, Tejpar, S., additional, and Van Cutsem, E., additional

Published
2018
Full Text
View/download PDF

10. Ultra-selection of metastatic colorectal cancer patients using next generation sequencing platform to improve clinical efficacy of anti-EGFR therapy

Author

Vidal, J., primary, Dalmeses, A., additional, Vivas, C. Santos, additional, Garcia-Carbonero, R., additional, García-Alfonso, P., additional, Carrato, A., additional, Elez, E., additional, Ortiz, M., additional, Losa, F., additional, Massutí, B., additional, Valladares-Ayerbes, M., additional, Manzano, J., additional, de Prado, J. Vieitez, additional, Gallego, J., additional, Grávalos, C., additional, Varela, M., additional, Azuara, D., additional, Tabernero, J., additional, Salazar, R., additional, Aranda, E., additional, Bellosillo, B., additional, and Montagut, C., additional

Published
2018
Full Text
View/download PDF

11. 625P - Clinical relevance of circulating tumour (ct)DNA genotyping for first-line cetuximab-based treatment monitoring in metastatic colorectal cancer (mCRC): A prospective multicentric study

Author

Barrull, J Vidal, Casadevall, D., Fernandez, M.C., Castro-Henriques, M., García-Alfonso, P., Martin-Cullell, B., Alonso-Orduna, V., Alonso, R M Rodríguez, Benavides, M., Vivas, C Santos, Fernández, E Elez, Garcia-Carbonero, R., Ferreiro, R., Manzano, J.L., Losa, F., Salazar, R., Tabernero, J., Aguilar, E Aranda, Bellosillo, B., and Viladot, C Montagut

Published
2019
Full Text
View/download PDF

12. 575P - RAS mutant allele fraction in plasma predicts benefit to anti-angiogenic based first-line treatment in metastatic colorectal cancer

Author

Martini, G., Elez, E., Mancuso, F.M., España, M A Gomez, Caratù, G., Matito, J., Martinez, G Argiles, Margalef, N Mulet, Morales, M J Ortiz, Montana, F J Ros, Garcia, A., Comas, R., Vivas, C Santos, Perez-Lopez, R., Nuciforo, P.G., Casanovas, O., Dienstmann, R., Tabernero, J., Aguilar, E Aranda, and Vivancos, A.

Published
2019
Full Text
View/download PDF

15. O-015 - A two arm phase II study of FOLFIRI in combination with standard or escalating dose of cetuximab as first line treatment for metastatic colorectal cancer: Everest 2 final results

Author

Chiritescu, G., Dumon, K., Mercadé, T. Macarulla, Lang, I., Vivas, C. Santos, Papai, Z., Janssens, J., Hendrickx, K., Pracht, M., Van den Eynde, M., Taïeb, J., Moons, V., Geboes, K., Van Laethem, J., Greil, R., Cervantes, A., Vergauwe, P., Ferrante, M., Vanderstraeten, E., Fridrik, M., Wöll, E., Limón, M., Rivera, F., Sagaert, X., Tejpar, S., and Van Cutsem, E.

Published
2018
Full Text
View/download PDF

16. O-006 - Ultra-selection of metastatic colorectal cancer patients using next generation sequencing platform to improve clinical efficacy of anti-EGFR therapy

Author

Vidal, J., Dalmeses, A., Vivas, C. Santos, Garcia-Carbonero, R., García-Alfonso, P., Carrato, A., Elez, E., Ortiz, M., Losa, F., Massutí, B., Valladares-Ayerbes, M., Manzano, J., de Prado, J. Vieitez, Gallego, J., Grávalos, C., Varela, M., Azuara, D., Tabernero, J., Salazar, R., Aranda, E., Bellosillo, B., and Montagut, C.

Published
2018
Full Text
View/download PDF

17. Ultra-selection of metastatic colorectal cancer patients using next-generation sequencing to improve clinical efficacy of anti-EGFR therapy.

Author

Vidal, J, Bellosillo, B, Vivas, C Santos, García-Alfonso, P, Carrato, A, Cano, M T, García-Carbonero, R, Élez, E, Losa, F, Massutí, B, Valladares-Ayerbes, M, Viéitez, J M, Manzano, J L, Azuara, D, Gallego, J, Pairet, S, Capellá, G, Salazar, R, Tabernero, J, and Aranda, E

Subjects
*GENETIC mutation, *COLORECTAL cancer, *ENDOTHELIAL growth factors, *METASTASIS, *CANCER patients, *TECHNOLOGY
Abstract

Background Extended RAS analysis is mandatory in metastatic colorectal cancer (mCRC) patients. The optimal threshold of RAS mutated subclones to identify patients most likely to benefit from antiepidermal growth factor receptor (EGFR) therapy is controversial. Our aim was to assess the clinical impact of detecting mutations in RAS, BRAF, PIK3CA and EGFRS492R in basal tissue tumour samples by using a highly sensitive next-generation sequencing (NGS) technology in mCRC patients treated with chemotherapy plus anti-EGFR or anti-vascular endothelial growth factor. Patients and methods Five hundred and eighty-one tumour samples from untreated mCRC patients from 7 clinical studies were collected. Mutational analysis was carried out by standard-of-care (therascreen pyro) with a sensitivity detection of 5% mutant allele fraction (MAF), and compared with NGS technology using 454GS Junior platform (Roche Applied Science, Germany) with a sensitivity of 1%. Molecular results were correlated with clinical outcomes. Results After quality assessment, 380 samples were evaluable for molecular analysis. Standard-of-care mutational analysis detected RAS, BRAFV600E or PIK3CA mutations in 56.05% of samples compared with 69.21% by NGS (P  =   0.00018). NGS identified coexistence of multiple low-frequency mutant alleles in 96 of the 263 mutated cases (36.5%; range 2–7). Response rate (RR), progression-free survival (PFS) and overall survival (OS) were increasingly improved in patients with RAS wild-type, RAS/BRAF wild-type or quadruple (KRAS/NRAS/BRAF/PIK3CA) wild-type tumours treated with anti-EGFR, assessed by standard-of-care. No additional benefit in RR, PFS or OS was observed by increasing the detection threshold to 1% by NGS. An inverse correlation between the MAF of the most prevalent mutation detected by NGS and anti-EGFR response was observed (P  =   0.039). EGFR S492R mutation was not detected in untreated samples. Conclusions No improvement in the selection of patients for anti-EGFR therapy was obtained by adjusting the mutation detection threshold in tissue samples from 5% to 1% MAF. Response to anti-EGFR was significantly better in patients with quadruple wild-type tumours. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results